Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

Research output: Contribution to journalReview articlepeer-review

Abstract

Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-VEGF treatment shows these vision gains can be maintained through 2 years. Further investigation is needed to explore the effects of long-term anti- VEGF therapy beyond 2 years.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalCurrent opinion in ophthalmology
Volume24
Issue number3
DOIs
StatePublished - May 1 2013

Keywords

  • Aflibercept
  • Age-Related Macular Degeneration
  • Bevacizumab
  • Choroidal Neovascularization
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this